The total return over the past 12 months is +0.14% vs. +16.94% for the S&P 500. So far it's up +4.11% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +0.14% | +4.45% | (33.26%) | (30.38%) | (41.86%) | (30.09%) |
| Total Return CAGR | +0.14% | +4.45% | (0.34%) | (14.92%) | (31.46%) | (20.90%) |
| Revenue CAGR | +13.53% | +2.18% | +84.92% | +75.30% | +0.86% | (7.81%) |
| Net Income CAGR | (501.16%) | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | (1008.22%) | +23.34% | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Gyre Therapeutics, Inc. (GYRE)
| Year | Start price | End price | GYRE Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $7.06 | $7.35 | +4.11% | +14.51% | (10.40%) |
| 2025 | $12.10 | $7.06 | (41.65%) | +17.72% | (59.37%) |
| 2024 | $25.69 | $12.10 | (52.90%) | +24.89% | (77.79%) |
| 2023 | $7.95 | $25.69 | +521.43% | +26.19% | +495.24% |
| 2022 | $13.65 | $7.95 | +124.81% | (18.17%) | +142.98% |
| 2021 | $94.65 | $13.65 | (85.58%) | +28.74% | (114.32%) |
| 2020 | $102.15 | $94.65 | (7.34%) | +18.37% | (25.71%) |
| 2019 | $118.35 | $102.15 | (13.69%) | +31.22% | (44.91%) |
| 2018 | $204.60 | $118.35 | (42.16%) | (4.56%) | (37.60%) |
| 2017 | $146.25 | $204.60 | +39.90% | +21.70% | +18.20% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
